Metformin Orifarm (Metformin Hydrochloride)

Metformin Orifarm, a biguanide antidiabetic agent, is indicated for conditions involving impaired glucose regulation.

• Type 2 diabetes mellitus: improves glycemic control and reduces hepatic glucose production.
• Prediabetes (impaired glucose tolerance): helps delay progression to type 2 diabetes when combined with lifestyle measures.
• Polycystic ovary syndrome (off‑label): may improve insulin resistance and menstrual regularity in affected women.

• Metformin acts primarily by inhibiting mitochondrial respiratory‑chain complex I, which reduces hepatic gluconeogenesis. This leads to decreased glucose output from the liver. It also enhances peripheral insulin sensitivity by increasing glucose uptake in muscle and adipose tissue and modestly lowers intestinal glucose absorption. The combined actions improve overall blood glucose levels without directly stimulating insulin secretion. Additionally, metformin may exert favorable effects on lipid metabolism and endothelial function.

Metformin Orifarm may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Gastrointestinal upset: nausea, abdominal discomfort, or loss of appetite.
• Diarrhea: frequent loose stools, especially during treatment initiation.
• Metallic taste: transient alteration in taste perception.
• Vitamin B12 deficiency: reduced absorption with long‑term use.

Serious or Rare Side Effects

• Lactic acidosis: rare but potentially fatal accumulation of lactate.
• Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Hepatic failure: marked liver enzyme elevations and impaired function.
• Hypoglycemia: when combined with insulin or insulin secretagogues.

Before initiating Metformin Orifarm, several precautionary measures should be considered to ensure safe use.

• Renal function assessment: evaluate creatinine clearance and avoid use in severe renal impairment.
• Monitor blood glucose: adjust therapy based on glycemic response and avoid hypoglycemia.
• Liver function evaluation: check hepatic enzymes, especially in patients with liver disease.
• Use caution in elderly: increased risk of lactic acidosis and renal decline.
• Avoid in acute heart failure: contraindicated during decompensated cardiac conditions.
• Store at room temperature: keep in the original container, protect from moisture and heat.

Metformin Orifarm can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Iodinated contrast agents: increase risk of lactic acidosis; discontinue metformin before and after imaging.
• Cimetidine: may raise metformin plasma concentrations.
• Alcohol: potentiates risk of lactic acidosis.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may mask hypoglycemia symptoms.
• ACE inhibitors and ARBs: can affect renal function, requiring dose adjustment.
• NSAIDs: may impair renal clearance of metformin.